Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health News, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how tainted drugs can reach consumers, how companies take advantage of rare disease drug rules and how FDA-approved generics often don't make it to market. She's also tracked pharmaceutical dollars to patient advocacy groups and members of Congress. Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC News, VICE News, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
The COVID-19 vaccine rollout faces another bottleneck: Pfizer and Moderna may be unable to fulfill contractual promises to deliver 100 million doses a piece to the federal government by March 31.
-
The federal government reaches an agreement with Pfizer to buy an additional 100 million doses of the COVID-19 vaccine. NPR explores what that means for the country's supply in the coming months.
-
The drugmakers will add an additional 100 million COVID-19 vaccine doses to the number that they are already supplying the government. They expect to deliver all the doses by July 31.
-
Despite being founded a decade ago, Moderna has never had a product make it to market. And the company registered its first factory with the Food and Drug Administration just this week. -
With Pfizer's COVID-19 vaccine awaiting Food and Drug Administration authorization, there's speculation about when the U.S. will buy another batch of doses and whether it already missed its chance.
-
A Pfizer board member says the government declined to buy more doses beyond the initial 100 million already agreed upon. Demand from other countries could complicate future purchases.
-
Most of the federal contracts with companies involved in the crash program to make COVID-19 vaccines haven't been made public. The lack of disclosure raises questions about accountability.
-
A panel of doctor and scientists raised questions about the expedited regulatory path the Food and Drug Administration is considering for COVID-19 vaccines.
-
The federal government is in charge of distributing one of the few treatment options for COVID-19: the antiviral drug remdesivir. But how are decisions made about which states need it most?
-
The president says the actions will lower drug prices, but policy experts say they will likely offer patients only minimal relief and may take months to implement, if they're implemented at all.
